OncoResponse racks up $22.5 mln
Houston, Texas-based OncoResponse, an immuno-oncology antibody discovery company, has raised $22.5 million in Series A financing. The investors included HT Family Office. In addition to the funding, OncoResponse has named Dr. Mike Gallatin, Dr. Albert Yu and Dr. Elizabeth Jaffee to its scientific advisory board.
9 March 2017•1 min read
